Referenssit
Zoran julkaisut:
CERT sekundääripreventiossa:
Hilvo et al. 2020 Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy JAHA 2020; 9(10), published online May 7, 2020. Linkki artikkeliin
Hilvo et al. 2020 Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur. Heart J. 2020; 41: 371-380. Linkki artikkeliin
Gencer et al. 2020 Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur. J. Prev. Cardiol. Published online Dec 2020. Linkki artikkeliin
Meeusen et al. 2020 Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. Clinica Chimica Acta 2020; 511:138–142. Linkki artikkeliin
Mantovani et al. 2020 Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. Diabetes & Metabolism, 46(2): 150-157. Linkki artikkeliin
Laaksonen et al. 2016 Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J. 2016; 37(25): 1967–1976. Linkki artikkeliin
Anroedh et al. 2018 Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J. Lipid Res. 2018, 59(6). Linkki artikkeliin
Cheng et al. 2015 Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2015; 243(2):560-6. Linkki artikkeliin
Tarasov et al. 2014 Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J. Clin. Endocrinol. Metab. 2014;99(1):E45-52. Linkki artikkeliin
CERT FINRISKI 2002 -väestötutkimuksessa:
Havulinna et al. 2016 Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. Arterioscler Thromb Vasc Biol. 2016; 36: 2424–2430. Linkki artikkeliin
CERT ja diabetesriski:
Hilvo et al. 2018 Ceramide stearic to palmitic acid ratio predicts incident diabetes. Diabetologia 2018; 61(6):1424–1434. Linkki artikkeliin
CERT suomalaisissa julkaisuissa:
Hilvo et al. 2019 Uusi lipiditesti sepelvaltimotautipotilaiden kardiovaskulaaririskin arviointiin. Duodecim 2019; 135: 1409.
Laaksonen 2018 Keramidimittaukset vakavien sydän- ja verisuonitapahtumien ja diabeteksen riskin arvioinnissa Yleislääkäri 5/2018, vsk 33: 26-28. Avaa artikkeli (pdf)
Laaksonen et al. 2018 Keramidit ja sepelvaltimotauti Duodecim 2018;134:456–64. Avaa artikkeli (pdf)
CERT-menetelmän analyyttinen validaatio:
Kauhanen et al. 2016 Development and validation of a high-throughput LC-MS/MS assay for routine measurement of molecular ceramides. Anal Bioanal Chem. 2016; 408(13): 3475-83. Linkki artikkeliin
Review-artikkeli keramideista:
Hilvo et al. 2020 Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification. Front. Endocrinol., 29 September 2020. Linkki artikkeliin
Ulkopuolisten julkaisut:
Öörni et al. 2020 Why and how increased plasma ceramides predict future cardiovascular events? Atherosclerosis. 2020 Dec; 314: P71-73. Linkki artikkeliin
Choi et al. 2021 Ceramides and other sphingolipids as drivers of cardiovascular disease. Nature Reviews Cardiology. Published March 26, 2021. Linkki artikkeliin
Petrocelli et al. 2020 Ceramide Biomarkers Predictive of Cardiovascular Disease Risk Increase in Healthy Older Adults After Bed Rest. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1663-1670. Linkki artikkeliin
Field et al. 2020 The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines. Front. Endocrinol. Published October 2020. Linkki artikkeliin
Kovilakath et al. 2020 Sphingolipids in the Heart: From Cradle to Grave. Front. Endocrinol. Published October 2020. Linkki artikkeliin
Meeusen et al. 2018 Plasma Ceramides – A Novel Predictor of Major Adverse Cardiovascular Events After Coronary Angiography. ATVB 2018; 38:1933–1939. Linkki artikkeliin
Carvalho et al. 2018 Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction JACC 2018, 3(2):163-175. Linkki artikkeliin
Mantovani et al. 2018 Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. Metabolism 2018, 85: 305-312. Linkki artikkeliin
Peterson et al. 2018 Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J. Am. Heart Assoc. 2018, 3;7(10). Linkki artikkeliin
Summers 2018 Could Ceramides Become the New Cholesterol. Cell Metabolism 2018, 27(2):276-280. Linkki artikkeliin
Wang DD et al. 2017 Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea). Circulation 2017, 135(21):2028-2040. Linkki artikkeliin
Chaurasia & Summers 2015 Ceramides – Lipotoxic Inducers of Metabolic Disorders. Trends Endocrinol. Metab. 2015, 26(10):538-50. Linkki artikkeliin
Kasumov et al. 2015 Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity 2015; 23:1414-21. Linkki artikkeliin
Chavez & Summers 2012 A ceramide-centric view of insulin resistance. Cell Metab. 2012, 15(5):585-94. Linkki artikkeliin
Bikman & Summers 2011 Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 2011, 121(11):4222-30. Linkki artikkeliin
Holland & Summers 2008 Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008, 29(4):381-402. Linkki artikkeliin